Viswanathan Kartik, Steward-Tharp Scott, Lubin Daniel, Saeed Faisal, Magliocca Kelly, Delfin Luvy, Bilodeau Elizabeth, Ilyas Ghulam, Ghossein Ronald, Xu Bin, Katabi Nora
Department of Pathology and Laboratory Medicine, Emory University Hospital Midtown, Atlanta, Georgia; Winship Cancer Institute, Emory University Hospital, Atlanta, Georgia.
Department of Pathology and Laboratory Medicine, Emory University Hospital Midtown, Atlanta, Georgia; Winship Cancer Institute, Emory University Hospital, Atlanta, Georgia.
Mod Pathol. 2025 May 28;38(9):100803. doi: 10.1016/j.modpat.2025.100803.
Polymorphous adenocarcinoma (PAC) is an uncommon salivary gland tumor demonstrating morphologic diversity, including conventional trabecular/tubular/reticular/single filing, cribriform/solid (cribriform adenocarcinoma of minor salivary gland [CASG]), and papillary (tumor with papillary growth pattern [TPAP]) patterns, with differing molecular alterations and biologic behavior. However, similar to other salivary gland tumors, whether a grading system incorporating mitotic count and necrosis could be applied to PACs is unclear. Retrospective histologic evaluation was performed on a bi-institutional cohort of 154 PACs, and a 2-tiered low-grade/high-g1rade (HG) system, incorporating mitoses ≥ 5 per 2 mm and/or necrosis, was applied. Molecular data, when available, and outcome status were collected. Statistical analyses, including univariate analysis and multivariable analysis, were performed. The most common site was palate (62.1%) followed by oral cavity (20.9%). Conventional PACs, CASG, and TPAP represented 56.6%, 39.5%, and 3.9% of cases, respectively. In the cohort, 12.3% demonstrated necrosis and 19.5% had mitosis ≥ 5 per 2 mm; HG criteria were met in 24.7% of cases. Follow-up data were available in 89.6% of cases. On univariate analysis, as per the 8th edition of the American Joint Committee on Cancer, T category, lymphovascular invasion, bone invasion, mitosis ≥ 5 per 2 mm, HG, necrosis, and CASG/TPAP morphologic subclassification had worse disease-specific survival and disease-free survival (DFS). PRKD fusion-positive cases affected only DFS, and 61.8% of the cases were of HG. On limited multivariable analysis, HG tumors had worse DFS. With the grading system, the 3-year, 5-year, and 10-year DFS rates were 97%, 91%, and 81% for low-grade tumors and 71%, 65%, and 46% for HG tumors. Although death from disease was limited (3.6%), the majority (80%) were of HG. PAC tumors generally have good outcomes; however, a 2-tiered grading system may identify a subset with worse clinical outcomes, independent of morphology and staging. Consideration should be given to evaluating not only the morphologic pattern but also for the presence of mitotic activity and necrosis in PACs.
多形性腺癌(PAC)是一种罕见的唾液腺肿瘤,具有形态学多样性,包括传统的小梁状/管状/网状/单列状、筛状/实性(小唾液腺筛状腺癌[CASG])和乳头状(具有乳头状生长模式的肿瘤[TPAP])模式,伴有不同的分子改变和生物学行为。然而,与其他唾液腺肿瘤类似,是否能将包含有丝分裂计数和坏死情况的分级系统应用于PAC尚不清楚。对一个由154例PAC组成的双机构队列进行了回顾性组织学评估,并应用了一种两级低级别/高级别(HG)系统,该系统纳入了每2毫米有丝分裂≥5个和/或坏死情况。如有可用的分子数据,则收集相关数据,并收集预后状况。进行了包括单变量分析和多变量分析在内的统计分析。最常见的部位是腭部(62.1%),其次是口腔(20.9%)。传统PAC、CASG和TPAP分别占病例的56.6%、39.5%和3.9%。在该队列中,12.3%的病例出现坏死,19.5%的病例每2毫米有丝分裂≥5个;24.7%的病例符合HG标准。89.6%的病例有随访数据。在单变量分析中,按照美国癌症联合委员会第8版标准,T类别、脉管侵犯、骨侵犯、每2毫米有丝分裂≥5个、HG、坏死以及CASG/TPAP形态学亚分类的疾病特异性生存率和无病生存率(DFS)较差。PRKD融合阳性病例仅影响DFS,且61.8%的病例为HG。在有限的多变量分析中,HG肿瘤的DFS较差。采用该分级系统,低级别肿瘤的3年、5年和10年DFS率分别为97%、91%和81%,HG肿瘤分别为71%、65%和46%。尽管死于疾病的情况有限(3.6%),但大多数(80%)为HG。PAC肿瘤总体预后良好;然而,一种两级分级系统可能会识别出临床预后较差的亚组,且与形态学和分期无关。对于PAC,不仅应考虑评估形态学模式,还应考虑有丝分裂活性和坏死情况。